CTIS2023-507418-28-00招募中1 期
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial - BO41932
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 825
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy, Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC), Performance status as follows: Participants aged = 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to < 18 years: Karnofsky score = 50%; Participants aged < 16 years: Lansky score = 50%, For participants aged = 18 and <18 years: adequate hematologic and end-organ function, Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment, Adequate recovery from most recent systemic or local treatment for cancer
排除标准
- •Current participation or enrollment in another therapeutic clinical trial, Any anticancer treatment within 2 weeks prior to start of study treatment (Please refer to the cohort-specific eligibility criteria for requirements on enrollment, if applicable), Whole brain radiotherapy within 14 days prior to start of study treatment, Stereotactic radiosurgery within 7 days prior to start of study treatment, Pregnant or breastfeeding, or intending to become pregnant during the study, History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
研究者
相似试验
暂停
2 期
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyRET fusion-positive solid tumors other than NSCLCJPRN-jRCT2031210670David Chen770
进行中（未招募）
1 期
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (Tapistry) Phase II Platform TrialSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-001847-16-PTF. Hoffmann-La Roche Ltd4
进行中（未招募）
1 期
To Study Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trialocally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by a validated NGS assayMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-001847-16-ITF. HOFFMANN - LA ROCHE LTD.650
进行中（未招募）
1 期
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (Tapistry) Phase II Platform Trialocally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by a validated NGS assayMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001847-16-DKF. Hoffmann-La Roche Ltd920
进行中（未招募）
1 期
To Study Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trialocally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by a validated NGS assayMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-001847-16-NLF. Hoffmann-La Roche Ltd600